{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T20:29:37Z","timestamp":1778358577986,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,20]]},"DOI":"10.7759\/cureus.86404","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T07:04:33Z","timestamp":1750403073000},"source":"Crossref","is-referenced-by-count":1,"title":["Evaluating the Safety and Efficacy of Moderate-Intensity Statin Combined With Ezetimibe in Elderly Patients With Atherosclerotic Cardiovascular Disease"],"prefix":"10.7759","author":[{"given":"Muhammad Usman","family":"Khalid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nosheen","family":"Pervaiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salma","family":"Sharif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Naveed Ali","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.20029","article-title":"Safety and efficacy of moderate-intensity statin with ezetimibe in elderly patients with atherosclerotic cardiovascular disease","volume":"297","author":"Cha JJ","year":"2025","unstructured":"Cha JJ, Kim JH, Hong SJ, et al.. Safety and efficacy of moderate-intensity statin with ezetimibe in elderly patients with atherosclerotic cardiovascular disease. J Intern Med. 2025, 297:400-8. 10.1111\/joim.20029","journal-title":"J Intern Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"73","author":"Grundy SM","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al.. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2019, 73:3168-209. 10.1016\/j.jacc.2018.11.002","journal-title":"J Am Coll Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach F","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al.. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020, 41:111-88. 10.1093\/eurheartj\/ehz455","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/clc.24334","article-title":"Safety and effectiveness of high-intensity statins versus low\/moderate-intensity statins plus ezetimibe in patients with atherosclerotic cardiovascular disease for reaching LDL-C goals: a systematic review and meta-analysis","volume":"47","author":"Soleimani H","year":"2024","unstructured":"Soleimani H, Mousavi A, Shojaei S, et al.. Safety and effectiveness of high-intensity statins versus low\/moderate-intensity statins plus ezetimibe in patients with atherosclerotic cardiovascular disease for reaching LDL-C goals: a systematic review and meta-analysis. Clin Cardiol. 2024, 47:e24334. 10.1002\/clc.24334","journal-title":"Clin Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2024.07.013","article-title":"Safety and efficacy of moderate-intensity statin plus ezetimibe versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease: a meta-analysis","volume":"18","author":"Kelly FA","year":"2024","unstructured":"Kelly FA, de Moraes FC, L\u00f4bo AO, Siebel VM, Leite M, de Almeida AM, Consolim-Colombo FM. Safety and efficacy of moderate-intensity statin plus ezetimibe versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease: a meta-analysis. J Clin Lipidol. 2024, 18:e893-904. 10.1016\/j.jacl.2024.07.013","journal-title":"J Clin Lipidol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2024.3911","article-title":"Alternative LDL cholesterol-lowering strategy vs high-intensity statins in atherosclerotic cardiovascular disease: a systematic review and individual patient data meta-analysis","volume":"10","author":"Lee YJ","year":"2025","unstructured":"Lee YJ, Hong BK, Yun KH, et al.. Alternative LDL cholesterol-lowering strategy vs high-intensity statins in atherosclerotic cardiovascular disease: a systematic review and individual patient data meta-analysis. JAMA Cardiol. 2025, 10:137-44. 10.1001\/jamacardio.2024.3911","journal-title":"JAMA Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006901","article-title":"Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE-IT (improved reduction of outcomes: vytorin efficacy international trial)","volume":"6","author":"Kato ET","year":"2017","unstructured":"Kato ET, Cannon CP, Blazing MA, et al.. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE-IT (improved reduction of outcomes: vytorin efficacy international trial). J Am Heart Assoc. 2017, 6:10.1161\/JAHA.117.006901","journal-title":"J Am Heart Assoc"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2012.02.016","article-title":"Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials","volume":"223","author":"Morrone D","year":"2012","unstructured":"Morrone D, Weintraub WS, Toth PP, et al.. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012, 223:251-61. 10.1016\/j.atherosclerosis.2012.02.016","journal-title":"Atherosclerosis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon CP","year":"2004","unstructured":"Cannon CP, Braunwald E, McCabe CH, et al.. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004, 350:1495-504. 10.1056\/NEJMoa040583","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Byty\u00e7i I","year":"2022","unstructured":"Byty\u00e7i I, Penson PE, Mikhailidis DP, et al.. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022, 43:3213-23. 10.1093\/eurheartj\/ehac015","journal-title":"Eur Heart J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00916-3","article-title":"Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial","volume":"30","author":"Kim BK","year":"2022","unstructured":"Kim BK, Hong SJ, . Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022, 30:380-90. 10.1016\/S0140-6736(22)00916-3","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.2487","article-title":"Treat-to-target or high-intensity statin in patients with coronary artery disease: a randomized clinical trial","volume":"329","author":"Hong SJ","year":"2023","unstructured":"Hong SJ, Lee YJ, Lee SJ, et al.. Treat-to-target or high-intensity statin in patients with coronary artery disease: a randomized clinical trial. JAMA. 2023, 329:1078-87. 10.1001\/jama.2023.2487","journal-title":"JAMA"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2019.0911","article-title":"2018 American Heart Association\/American College of Cardiology\/Multisociety Guideline on the management of blood cholesterol-secondary prevention","volume":"4","author":"Grundy SM","year":"2019","unstructured":"Grundy SM, Stone NJ. 2018 American Heart Association\/American College of Cardiology\/Multisociety Guideline on the management of blood cholesterol-secondary prevention. JAMA Cardiol. 2019, 4:589-91. 10.1001\/jamacardio.2019.0911","journal-title":"JAMA Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.02.071","article-title":"Statin-associated side effects","volume":"67","author":"Thompson PD","year":"2016","unstructured":"Thompson PD, Panza G, Zaleski A, Taylor B. Statin-associated side effects. J Am Coll Cardiol. 2016, 67:2395-410. 10.1016\/j.jacc.2016.02.071","journal-title":"J Am Coll Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.064623","article-title":"Chronic coronary disease guidelines","volume":"148","author":"Rao SV","year":"2023","unstructured":"Rao SV, Reynolds HR, Hochman JS. Chronic coronary disease guidelines. Circulation. 2023, 148:729-31. 10.1161\/CIRCULATIONAHA.123.064623","journal-title":"Circulation"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2022-000134","article-title":"Safety of ezetimibe in lipid-lowering treatment: systematic review and meta-analysis of randomised controlled trials and cohort studies","volume":"1","author":"Wang Y","year":"2022","unstructured":"Wang Y, Zhan S, Du H, et al.. Safety of ezetimibe in lipid-lowering treatment: systematic review and meta-analysis of randomised controlled trials and cohort studies. BMJ Med. 2022, 1:e000134. 10.1136\/bmjmed-2022-000134","journal-title":"BMJ Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.02.007","article-title":"Combination moderate-intensity statin\u00a0and ezetimibe therapy for elderly patients with atherosclerosis","volume":"81","author":"Lee SH","year":"2023","unstructured":"Lee SH, Lee YJ, Heo JH, et al.. Combination moderate-intensity statin\u00a0and ezetimibe therapy for elderly patients with atherosclerosis. J Am Coll Cardiol. 2023, 81:1339-49. 10.1016\/j.jacc.2023.02.007","journal-title":"J Am Coll Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101933","article-title":"Efficacy and safety of moderate-intensity statin with ezetimibe combination therapy in patients after percutaneous coronary intervention: a post-hoc analysis of the RACING trial","volume":"58","author":"Park JI","year":"2023","unstructured":"Park JI, Lee SJ, Hong BK, et al.. Efficacy and safety of moderate-intensity statin with ezetimibe combination therapy in patients after percutaneous coronary intervention: a post-hoc analysis of the RACING trial. EClinicalMedicine. 2023, 58:101933. 10.1016\/j.eclinm.2023.101933","journal-title":"EClinicalMedicine"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2017.02.099","article-title":"A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): ezetimibe and rosuvastatin versus high-dose rosuvastatin","volume":"235","author":"Ran D","year":"2017","unstructured":"Ran D, Nie HJ, Gao YL, et al.. A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): ezetimibe and rosuvastatin versus high-dose rosuvastatin. Int J Cardiol. 2017, 235:49-55. 10.1016\/j.ijcard.2017.02.099","journal-title":"Int J Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.976","article-title":"Effect of combination therapy of ezetimibe and atorvastatin on remnant lipoprotein versus double atorvastatin dose in Egyptian diabetic patients","volume":"58","author":"El-Tamalawy MM","year":"2018","unstructured":"El-Tamalawy MM, Ibrahim OM, Hassan TM, El-Barbari AA. Effect of combination therapy of ezetimibe and atorvastatin on remnant lipoprotein versus double atorvastatin dose in Egyptian diabetic patients. J Clin Pharmacol. 2018, 58:34-41. 10.1002\/jcph.976","journal-title":"J Clin Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","year":"2019","unstructured":"Efficacy and safety of statin therapy in older people. a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019, 393:407-15. 10.1016\/S0140-6736(18)31942-1","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/374472-evaluating-the-safety-and-efficacy-of-moderate-intensity-statin-combined-with-ezetimibe-in-elderly-patients-with-atherosclerotic-cardiovascular-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T07:04:33Z","timestamp":1750403073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/374472-evaluating-the-safety-and-efficacy-of-moderate-intensity-statin-combined-with-ezetimibe-in-elderly-patients-with-atherosclerotic-cardiovascular-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.86404","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,20]]}}}